Med. praxi. 2011;8(11):452-454
Gouty arthritis
- Revmatologický ústav, Praha
Gouty arthritis is the most common crystal induced arthritis, caused by monosodium urate crystals deposition. Gouty arthritis can be
present as an acute gouty arthritis affecting usually the big toe of the foot, or a chronic gouty arthritis with rather polyarticular involvement.
In the laboratory tests elevated serum level of uric acid is usually found, also erytrocytes sedimentation rate and serum CRP level
may be increased as well. At the X-rays of the chronic gout typical round-shaped bone erosions can be seen. Acute gouty arthritis should
be treated with colchicine and/or nonsteroidal antiinflammatory drugs (NSAIDs), but the dose of allopurinol should not be changed nor
it should be introduced as a new drug. In the intercritical period uric acid level should be decreased with the diet and allopurinol, in
chronic gouty arthritis apart of hypouricemic therapy also NSAIDs and small doses of colchicin are given. Febuxostat is a new alternative
od allopurinol in treatment of hyperuricemia.
Keywords: gout, crystal induced arthropathies, uric acid, natrium urate, allopurinol, febuxostat
Published: January 1, 2011 Show citation
References
- McCarty DJ, Hollander JL. Identification of urate crystals in gouty synovial fluid. Ann Intern Med 1961; 54: 452-460.
Go to original source... 
Go to PubMed... - Lawrence RC, Helmick CG, Arnett FC, Deyo RA, Felson DT, Giannini EH, et al. Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States. Arthritis Rheum 1998; 41: 778-799. Go to original source...
- Mikuls TR, Farrar JT, Bilker WB, Fernandes S, Schumacher HR, Saag KG. Gout epidemiology: results from the UK General Practice Research Database, 1990-1999. Ann Rheum Dis 2005; 64: 2. Go to original source... Go to PubMed...
- Campion EW, Glynn RJ, DeLabry LO. Asymptomatic hyperuricemia. Am J Med 1987; 82: 421-426. Go to original source... Go to PubMed...
- Wallace SL, Robinson H, Masi TA, et al. Preliminary criteria for the classification of the acute arthritis of primary gout. Arthritis Rheum 1977; 20: 895-900. Go to original source... Go to PubMed...
- Zhang W, Roberty M, Pascal E, et al. EULAR evidence based recommendations for gout. Part I: Diagnosis. Report of a task force of the standing committee for international clinical studies including therapeutics (ESCISIT). Ann Rheum Dis 2006; 65: 1301-1311. Go to original source... Go to PubMed...
- Zhang W, Roberty M, Bardin T, et al. EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee For International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2006; 65: 1312-1324. Go to original source... Go to PubMed...
- Becker MA, Schumacher HR, Espinoza LR, Wells AF, MacDonald P, Lloyd E, et al. The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial. Arthritis Res Ther 2010; 12(2): R63. Go to original source... Go to PubMed...
- Wortmann RL, Macdonald PA, Hunt B, Jackson RL. Effect of prophylaxis on gout flares after the initiation of urate-lowering therapy: analysis of data from three phase III trials. Clin Ther 2010; 32(14): 2386-2397. Go to original source... Go to PubMed...